文献速递银屑病与炎症性皮肤病皮肤感染

托法替布治疗银屑病患者的带状疱疹风险

Herpes zoster in psoriasis patients treated with tofacitinib.
PubMed 文献 · J Am Acad Dermatol · 2017-01-01

基于托法替布银屑病开发项目2/3期及长期延展数据,计算带状疱疹发生率并评估危险因素。亚裔、10mg每日两次、既往生物制剂使用及年龄增长与风险升高相关。

要点

  • 托法替布组带状疱疹发生率为2.55/100患者年,安慰剂组无病例。
  • 亚裔、10mg每日两次、既往生物制剂使用和年龄增长增加带状疱疹风险。
  • 多数患者带状疱疹后继续或恢复托法替布治疗,未发生脑炎、内脏受累或死亡。

核心结论

  • 托法替布相对安慰剂与带状疱疹风险升高相关。
  • 亚裔、年龄增长、较高剂量及既往生物制剂暴露与风险升高相关。

研究设计与样本

  • 采用托法替布银屑病开发项目2期、3期及长期延展数据计算带状疱疹发生率。
  • 使用Cox比例风险模型评估带状疱疹潜在危险因素。

主要发现

  • 安慰剂组无患者发生带状疱疹,依那西普组2例发生(发生率2.68)。
  • 9例(7%)住院,8例(6%)为多皮节带状疱疹,无脑炎、内脏受累或死亡。
  • 121例(93%)托法替布组患者在带状疱疹后继续或恢复用药。
  • 危险因素包括亚裔(HR 2.92)、托法替布10mg每日两次(对比5mg每日两次;HR 1.72)、既往生物制剂使用(HR 1.72)和年龄增长(HR 1.30)。

关键数值与推荐

  • 托法替布组带状疱疹发生率2.55/100患者年,依那西普组2.68/100患者年。
  • 亚裔HR 2.92;10mg每日两次对比5mg每日两次HR 1.72;既往生物制剂使用HR 1.72;年龄增长HR 1.30。

临床怎么用

  • 银屑病患者使用托法替布前应评估带状疱疹风险因素,包括亚裔、年龄、剂量和既往生物制剂使用。
  • 发生带状疱疹后多数患者可继续或恢复托法替布治疗,但需关注住院和多皮节受累风险。

局限性

  • 对其他银屑病人群的可推广性可能有限。
  • 未研究带状疱疹疫苗接种的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor. Immunomodulatory therapies can increase the risk for herpes zoster (HZ) in patients with psoriasis. OBJECTIVE: To evaluate the relationship between tofacitinib use and HZ risk. METHODS: We used phases 2 and 3 and long-term extension (LTE) data from the tofacitinib development program in psoriasis to calculate HZ incidence rates (IR; events per 100 patient-years); potential HZ risk factors were evaluated using Cox-proportional hazard models. RESULTS: One hundred thirty (3.6%) patients on tofacitinib (IR 2.55), no patients on placebo, and 2 using etanercept (IR 2.68) developed HZ. Nine patients (7%) were hospitalized, and 8 (6%) had multidermatomal HZ; no encephalitis, visceral involvement, or deaths occurred. In total, 121 (93%) patients on tofacitinib continued or resumed use after HZ. HZ risk factors included Asian descent (hazard ratio [HR] 2.92), using tofacitinib 10 mg twice daily (vs 5 mg twice daily; HR 1.72), prior use of biologics (HR 1.72), and older age (HR 1.30). LIMITATIONS: Generalizability to other psoriasis populations might be limited. The effect of HZ vaccination was not studied. CONCLUSION: Tofacitinib is associated with increased HZ risk relative to placebo. Asian race, increasing age, higher dose, and prior biologic exposure are associated with heightened risk.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017. PMID: 28711084. doi:10.1016/j.jaad.2017.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。